{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:15:43Z","timestamp":1780910143151,"version":"3.54.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaad.2025.10.091","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:18:55Z","timestamp":1761617935000},"page":"739-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to Papp et al, \u201cEfficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study\u201d"],"prefix":"10.1016","volume":"94","author":[{"given":"Christiaan H.","family":"Noot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary H.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaad.2025.10.091_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/acr.24782","article-title":"Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment","volume":"74","author":"Sumpton","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.jaad.2025.10.091_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70094","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design","volume":"17","author":"Ucpinar","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaad.2025.10.091_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.05.1053","article-title":"Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.091_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.091_bib5","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225030890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225030890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:56:42Z","timestamp":1780909002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225030890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0190962225030890"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.091","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Papp et al, \u201cEfficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}